Argenx Data Shows Remarkable VYVGART Benefit for MG Patients
Argenx presented a sweep of new Vyvgart data at AANEM/MGFA 2025, headlined by the phase 3 ADAPT SERON trial...
eClinical Tech News
Ianalumab Reduces Sjögren’s Disease Activity in Phase III
Novartis reported positive Phase 3 results for ianalumab in Sjögren’s disease, with the 300 mg monthly subcutaneous regimen meeting...
New Hope: Rosnilimab Trial Shows Positive Arthritis Results
AnaptysBio reported late-breaking results from its 424-patient Phase 2b RA study showing that rosnilimab, a selective pathogenic T cell...
Achieve Life Sciences Sets Q3 Financial Results Call Nov 6
Achieve Life Sciences will report third-quarter results on November 6 and deliver a corporate update on cytisinicline, its late-stage...
Paris Hilton Shares The Truth About Her ADHD Journey, Treatment
Collegium Pharmaceutical has launched a high-profile awareness collaboration with Paris Hilton centered on adult ADHD, with plans for Hilton...
Medicus & GSA Collaboration Offers Hope for Gorlin Syndrome
Medicus Pharma has entered a strategic collaboration with the Gorlin Syndrome Alliance to pursue an Expanded Access IND for...
Kamada to Present at the Stifel 2025 Healthcare Conference
Kamada will brief investors at the Stifel 2025 Healthcare Conference in New York on November 12 at 9:20 a.m....
Seres Therapeutics Gets $3.6M Award for SER-155 Formulation
Seres Therapeutics has secured up to $3.6 million in additional non-dilutive funding from CARB-X to develop and manufacture an...
Fulcrum Therapeutics’ Q3 2025 Financial Results Highlights
Fulcrum Therapeutics reported new Phase 1b data for its oral EED inhibitor, pociredir, in sickle cell disease, showing dose-dependent,...
Important ADMA Biologics Q3 2025 Financial Results Update
ADMA Biologics will report third-quarter 2025 results on November 5, alongside a call to discuss performance across its plasma-derived...